794554-75-9

Basic information

• Product Name: Benzenecarboximidamide, N-[(chloroacetyl)oxy]-4-fluoro-
• CAS NO: 794554-75-9
• Molecular Formula: C9H8ClFN2O2
• Molecular Weight: 230.626
• Mol File: 794554-75-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzenecarboximidamide, N-[(chloroacetyl)oxy]-4-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenecarboximidamide, N-[(chloroacetyl)oxy]-4-fluoro-(794554-75-9)
• EPA Substance Registry System: Benzenecarboximidamide, N-[(chloroacetyl)oxy]-4-fluoro-(794554-75-9)

Safety Data

• Hazardous Substances Data: 794554-75-9(Hazardous Substances Data)

Upstream product

• 1194-02-1 4-fluorobenzonitrile 
• 22179-78-8 4-fluoro-benzamidoxime 
• 79-04-9 chloroacetyl chloride 
• 22179-78-8 (Z)-4-fluoro-N'-hydroxybenzimidamide 

Downstream Products

• 721428-34-8 3-(4-fluorophenyl)-5-(chloromethyl)-1,2,4-oxadiazole 

Relevant articles and documents

Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors

Using Entinostat as a lead compound, 2-aminobenzamide and hydroxamate derivatives have been designed and synthesized. The entire target compounds were investigated for their in vitro antiproliferative activities using the MTT-based assay against five human cancer cell lines including U937, A549, NCI-H661, MDA-MB-231 and HCT116. 2-Aminobenzamide series of compounds (10a-10j) demonstrated the most significant inhibition against human acute monocytic myeloid leukemia cell line U937, but no or poor activities against two human lung cancer cell lines. Furthermore, the target compounds were screened for their inhibitory activities against HDAC 1, 2, and 8. 2-Aminobenzamide derivatives (10) manifested a higher selectivity for HDAC 1 over HDAC 2, but were not active against HDAC 8. In contrast, most hydroxamate derivatives (11) inhibit HDAC 8 with lower IC50 values than SAHA and Entinostat. Docking study with selected compounds 10f and 11a revealed that the compounds might bind tightly to the binding pockets in HDAC 2 and HDAC 8, respectively. The results suggest that they may be promising lead compounds for the development of novel anti-tumor drug potentially via inhibiting HDACs.

The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma

Adenosine has been suggested to play a role in asthma, possibly via activation of A2B adenosine receptors on mast cells and other pulmonary cells. We describe our initial efforts to discover a xanthine based selective A2B AdoR antagonist that resulted in the discovery of CVT-5440, a high affinity A2B AdoR antagonist with good selectivity (A2B AdoR Ki = 50 nM, selectivity A1 > 200: A2A > 200: A3 > 167).